Peer-reviewedCC BYJAAD case reports
Sustained multisite response to anifrolumab in refractory Chilblain lupus erythematosus.
4 affiliations
- 1Penn State College of Medicine, Hershey, Pennsylvania.
- 2Division of Pediatric Rheumatology, Department of Pediatrics, Golisano Children's Hospital, Penn State Health, Hershey, Pennsylvania.
- 3Department of Dermatology, Penn State Health, Hershey, Pennsylvania.
- 4Department of Public Health Sciences, Penn State Health, Hershey, Pennsylvania.
Related
- Sustained Tocilizumab and Adjunctive HydroBox Therapy in Refractory Takayasu Arteritis: An 11-year Case Report
- Demodex Folliculitis Following Anifrolumab Infusion.
- Palmoplantar Pustulosis Induced by Intravenous Anifrolumab: An Emerging Dermatologic Adverse Event?
- Fatigue outcomes with anifrolumab in low-disease-activity SLE: DNA damage in plasmacytoid dendritic cells as a candidate biomarker for responders.
- Anifrolumab, a potential treatment for ADA2 deficiency
BibTeX
@article{john2026sustained,
title = {{Sustained multisite response to anifrolumab in refractory Chilblain lupus erythematosus.}},
author = {Sarah John and Lisabeth V Scalzi and Galen Foulke and Matthew Helm},
journal = {JAAD case reports},
year = {2026},
month = sep,
doi = {10.1016/j.jdcr.2026.08.051},
url = {https://europepmc.org/article/MED/42903883},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sustained multisite response to anifrolumab in refractory Chilblain lupus erythematosus.
AU - Sarah John
AU - Lisabeth V Scalzi
AU - Galen Foulke
AU - Matthew Helm
PY - 2026
DA - 2026/09/06
JO - JAAD case reports
DO - 10.1016/j.jdcr.2026.08.051
UR - https://europepmc.org/article/MED/42903883
SN - 2352-5126
ER -